Clinical Trial Detail

NCT ID NCT02386826
Title INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors SCRI Development Innovations, LLC
Indications

colorectal cancer

glioblastoma multiforme

renal cell carcinoma

gliosarcoma

Therapies

Bevacizumab + INC280

Age Groups: adult

Additional content available in CKB BOOST